Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (41-50 of 247) with videos related to

Pageof 25
Sort By:
Clinical Breast Cancer|July 7, 2011
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancerDenise A Yardley, Eric Raefsky, Raul Castillo, et al.
The Oncologist|August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignanciesHoward A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
Cancer|March 17, 2009
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neckJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Investigational New Drugs|May 2, 2012
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of METJeffrey R Infante, Terence Rugg, Michael Gordon, et al.
Cancer Investigation|August 2, 2017
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)David R Spigel, Tarek M Mekhail, David Waterhouse, et al.
Cancer Chemotherapy and Pharmacology|May 1, 2008
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyAhmad Awada, Martine J Piccart, Suzanne F Jones, et al.
Cancer|June 1, 2012
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerMuralidhar Beeram, Ian E Krop, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphomaJohn D Hainsworth, Sharlene Litchy, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Investigational New Drugs|May 15, 2002
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignanciesSuzanne Jones, John Hainsworth, Howard A Burris, et al.
Pageof 25

Showing results (41-50 of 247) with videos related to

Sort By:
Pageof 25
Clinical Breast Cancer|July 7, 2011
Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancerDenise A Yardley, Eric Raefsky, Raul Castillo, et al.
The Oncologist|August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignanciesHoward A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.
Cancer|March 17, 2009
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neckJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Investigational New Drugs|May 2, 2012
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of METJeffrey R Infante, Terence Rugg, Michael Gordon, et al.
Cancer Investigation|August 2, 2017
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)David R Spigel, Tarek M Mekhail, David Waterhouse, et al.
Cancer Chemotherapy and Pharmacology|May 1, 2008
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyAhmad Awada, Martine J Piccart, Suzanne F Jones, et al.
Cancer|June 1, 2012
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancerMuralidhar Beeram, Ian E Krop, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphomaJohn D Hainsworth, Sharlene Litchy, Howard A Burris, et al.
European Journal of Cancer (Oxford, England : 1990)|January 9, 2013
Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancerJeffrey R Infante, Johanna C Bendell, Laura Williams Goff, et al.
Investigational New Drugs|May 15, 2002
Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignanciesSuzanne Jones, John Hainsworth, Howard A Burris, et al.
Pageof 25